{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:11:13Z","timestamp":1792069873428,"version":"4.4.0"},"reference-count":52,"publisher":"The Company of Biologists","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007880","name":"Associazione Bianca Garavaglia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007880","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023296","name":"Alleanza Contro il Cancro","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023296","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>This study exploited a novel patient-derived xenograft (PDX) of desmoplastic small round cell tumor (DSRCT), which reproduces histomorphological and molecular characteristics of the clinical tumor, to assess the activity of cytotoxic and targeted anticancer agents. Antitumor effect was moderate for doxorubicin, pazopanib and larotrectenib [maximum tumor volume inhibition (max TVI), 55-66%], while trabectedin had higher activity (max TVI, 82%). Vinorelbine, irinotecan and eribulin achieved nearly complete tumor growth inhibition (max TVI, 96-98%), although tumors regrew after the end of treatment. The combination of irinotecan with either eribulin or trabectedin resulted in complete responses, which were maintained until the end of the experiment for irinotecan plus trabectedin. Irinotecan-based combinations nearly abrogated the expression of proteins of the G2\/M checkpoint, preventing cell entrance in mitosis, and induced apoptotic and necroptotic cell death. Consistently, irinotecan plus trabectedin resulted in reprogramming of DSCRT transcriptome, with downregulation of E2F targets, G2\/M checkpoint and mitotic spindle gene sets. This study emphasizes the importance of patient-derived preclinical models to explore new treatments for DSRCT and fosters clinical investigation into the activity of irinotecan plus trabectedin.<\/jats:p>","DOI":"10.1242\/dmm.049649","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:51:15Z","timestamp":1683611475000},"source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft"],"prefix":"10.1242","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-9095","authenticated-orcid":false,"given":"Valentina","family":"Zuco","sequence":"first","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4815-6293","authenticated-orcid":false,"given":"Sandro","family":"Pasquali","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"},{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 2 Sarcoma Service, Department of Surgery , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tortoreto","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-2639","authenticated-orcid":false,"given":"Stefano","family":"Percio","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-0961","authenticated-orcid":false,"given":"Valentina","family":"Doldi","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9728-3120","authenticated-orcid":false,"given":"Marta","family":"Barisella","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 3 Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-210X","authenticated-orcid":false,"given":"Paola","family":"Collini","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 3 Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6743-1935","authenticated-orcid":false,"given":"Gian Paolo","family":"Dagrada","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 3 Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-1712","authenticated-orcid":false,"given":"Silvia","family":"Brich","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 3 Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-3724","authenticated-orcid":false,"given":"Patrizia","family":"Gasparini","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 4 Epigenomics and biomarkers of solid tumors, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-424X","authenticated-orcid":false,"given":"Marco","family":"Fiore","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 2 Sarcoma Service, Department of Surgery , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-7883","authenticated-orcid":false,"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 5 Pediatric Oncology Unit, Department of Cancer Medicine , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-7224","authenticated-orcid":false,"given":"Anna Maria","family":"Frezza","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 6 Medical Oncology Unit 2, Department of Cancer Medicine , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-3534","authenticated-orcid":false,"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 2 Sarcoma Service, Department of Surgery , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-8666","authenticated-orcid":false,"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 6 Medical Oncology Unit 2, Department of Cancer Medicine , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4724-0517","authenticated-orcid":false,"given":"Andrea","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 5 Pediatric Oncology Unit, Department of Cancer Medicine , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0890","authenticated-orcid":false,"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[{"name":"Fondazione IRCSS Istituto Nazionale dei Tumori 1 Molecular Pharmacology Unit, Department of Experimental Oncology , , 20133 Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"2023061410240644900_DMM049649C1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13569-017-0076-4","article-title":"Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's)","volume":"7","author":"Betrian","year":"2017","journal-title":"Clin. Sarcoma. Res."},{"key":"2023061410240644900_DMM049649C2","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol."},{"key":"2023061410240644900_DMM049649C3","doi-asserted-by":"publisher","first-page":"e28951","DOI":"10.1002\/pbc.28951","article-title":"Integrating irinotecan in standard chemotherapy: a novel dose-density combination for high-risk pediatric sarcomas","volume":"68","author":"Bisogno","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"2023061410240644900_DMM049649C4","doi-asserted-by":"publisher","first-page":"e101654","DOI":"10.15252\/embj.2019101654","article-title":"Xenograft and organoid model systems in cancer research","volume":"38","author":"Bleijs","year":"2019","journal-title":"EMBO J."},{"key":"2023061410240644900_DMM049649C5","first-page":"3683","article-title":"Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy","volume":"34","author":"Brunetti","year":"2014","journal-title":"Anticancer Res."},{"key":"2023061410240644900_DMM049649C6","doi-asserted-by":"publisher","first-page":"1278268","DOI":"10.1155\/2017\/1278268","article-title":"Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations","volume":"2017","author":"Bulbul","year":"2017","journal-title":"Sarcoma"},{"key":"2023061410240644900_DMM049649C7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/cncr.20544","article-title":"Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol","volume":"101","author":"Casanova","year":"2004","journal-title":"Cancer"},{"key":"2023061410240644900_DMM049649C8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2023061410240644900_DMM049649C9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/CAD.0000000000000536","article-title":"Clinical activity of eribulin in advanced desmoplastic small round-cell tumor","volume":"28","author":"Emambux","year":"2017","journal-title":"Anti-Cancer Drugs"},{"key":"2023061410240644900_DMM049649C10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/pbc.20682","article-title":"Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor","volume":"49","author":"Ferrari","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"2023061410240644900_DMM049649C11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0300891621995250","article-title":"Multiagent chemotherapy including IrIVA regimen and maintenance therapy in the treatment of desmoplastic small round cell tumor","volume":"108","author":"Ferrari","year":"2022","journal-title":"Tumori"},{"key":"2023061410240644900_DMM049649C12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/1120009X.2022.2067706","article-title":"Trabectedin-irinotecan combination is effective in relapsed desmoplastic small round cell tumor: report of two cases","volume":"35","author":"Ferrari","year":"2022","journal-title":"J. Chemother."},{"key":"2023061410240644900_DMM049649C13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-3329-4-7","article-title":"Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience","volume":"4","author":"Frezza","year":"2014","journal-title":"Clin. Sarcoma. Res."},{"key":"2023061410240644900_DMM049649C14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2045-3329-4-3","article-title":"Trabectedin for desmoplastic small round cell tumours: a possible treatment option?","volume":"4","author":"Frezza","year":"2014","journal-title":"Clin. Sarcoma. Res."},{"key":"2023061410240644900_DMM049649C15","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1093\/bioinformatics\/btx346","article-title":"karyoploteR: an R\/Bioconductor package to plot customizable genomes displaying arbitrary data","volume":"33","author":"Gel","year":"2017","journal-title":"Bioinformatics"},{"key":"2023061410240644900_DMM049649C16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00000478-199106000-00001","article-title":"Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals","volume":"15","author":"Gerald","year":"1991","journal-title":"Am. J. Surg. Pathol."},{"key":"2023061410240644900_DMM049649C17","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.1998.16.9.3028","article-title":"Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants","volume":"16","author":"Gerald","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"2023061410240644900_DMM049649C18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","article-title":"The role of necroptosis in cancer biology and therapy","volume":"18","author":"Gong","year":"2019","journal-title":"Mol. Cancer"},{"key":"2023061410240644900_DMM049649C19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCO.0000000000000373","article-title":"Preclinical models for translational sarcoma research","volume":"29","author":"Hamacher","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"2023061410240644900_DMM049649C20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/abbs\/gmr109","article-title":"Targeting protein lysine methylation and demethylation in cancers","volume":"44","author":"He","year":"2012","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2023061410240644900_DMM049649C21","doi-asserted-by":"publisher","first-page":"7461783","DOI":"10.1155\/2016\/7461783","article-title":"Trabectedin followed by irinotecan can stabilize disease in advanced translocation-positive sarcomas with acceptable toxicity","volume":"2016","author":"Herzog","year":"2016","journal-title":"Sarcoma"},{"key":"2023061410240644900_DMM049649C22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11523-012-0251-8","article-title":"Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series","volume":"8","author":"Italiano","year":"2013","journal-title":"Target Oncol."},{"key":"2023061410240644900_DMM049649C23","doi-asserted-by":"publisher","DOI":"10.1101\/060012","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2019","journal-title":"bioRxiv"},{"key":"2023061410240644900_DMM049649C24","first-page":"2837","article-title":"Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor","volume":"54","author":"Ladanyi","year":"1994","journal-title":"Cancer Res."},{"key":"2023061410240644900_DMM049649C25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments","volume":"28","author":"Leek","year":"2012","journal-title":"Bioinformatics"},{"key":"2023061410240644900_DMM049649C26","first-page":"3522","article-title":"Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors","volume":"6","author":"Liu","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"2023061410240644900_DMM049649C27","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1007\/s12032-010-9687-9","article-title":"Activity of trabectidin in desmoplastic small round cell tumor","volume":"28","author":"Lopez-Gonzalez","year":"2011","journal-title":"Medi. Oncol."},{"key":"2023061410240644900_DMM049649C28","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.26355\/eurrev_202006_21486","article-title":"LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217","volume":"24","author":"Ma","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2023061410240644900_DMM049649C29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol."},{"key":"2023061410240644900_DMM049649C30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S1470-2045(19)30826-5","article-title":"Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial","volume":"21","author":"Martin-Broto","year":"2020","journal-title":"Lancet Oncol."},{"key":"2023061410240644900_DMM049649C31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1001\/jamaoncol.2018.2146","article-title":"Optimal multimodal treatment for desmoplastic small round cell tumors","volume":"4","author":"Mir","year":"2018","journal-title":"JAMA Oncol."},{"key":"2023061410240644900_DMM049649C52","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J. Natl Cancer Inst"},{"key":"2023061410240644900_DMM049649C32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/01.LAB.0000028059.92642.03","article-title":"Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1","volume":"82","author":"Nishio","year":"2002","journal-title":"Lab. Invest."},{"key":"2023061410240644900_DMM049649C33","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/1078-0432.CCR-20-2585","article-title":"Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor","volume":"27","author":"Ogura","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2023061410240644900_DMM049649C34","doi-asserted-by":"publisher","first-page":"2018:PO.18.00183","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","author":"Okamura","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"2023061410240644900_DMM049649C35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1139\/O09-053","article-title":"H3 phosphorylation: dual role in mitosis and interphase","volume":"87","author":"Perez-Cadahia","year":"2009","journal-title":"Biochem. Cell Biol."},{"key":"2023061410240644900_DMM049649C36","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"2023061410240644900_DMM049649C37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2023061410240644900_DMM049649C38","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-19-1822","article-title":"Evaluation of eribulin combined with irinotecan for treatment of pediatric cancer xenografts","volume":"26","author":"Robles","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2023061410240644900_DMM049649C39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/(SICI)1096-911X(199911)33:5&lt;500::AID-MPO12&gt;3.0.CO;2-X","article-title":"Successful clinical response to irinotecan in desmoplastic round blue cell tumor","volume":"33","author":"Rosoff","year":"1999","journal-title":"Med. Pediatr. Oncol."},{"key":"2023061410240644900_DMM049649C40","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.lfs.2021.120268","article-title":"miR-142-3p simultaneously targets HMGA1, HMGA2, HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo metastatic potential of human cervical cancer cells","volume":"291","author":"Sharma","year":"2022","journal-title":"Life Sci."},{"key":"2023061410240644900_DMM049649C41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12885-018-4135-x","article-title":"Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Cancer"},{"key":"2023061410240644900_DMM049649C42","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-20-0722","article-title":"Comprehensive molecular profiling of desmoplastic small round cell tumor","volume":"19","author":"Slotkin","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"2023061410240644900_DMM049649C43","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"key":"2023061410240644900_DMM049649C44","doi-asserted-by":"publisher","first-page":"dmm047621","DOI":"10.1242\/dmm.047621","article-title":"Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling","volume":"15","author":"Smith","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"2023061410240644900_DMM049649C45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.002","article-title":"Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin\/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour","volume":"76","author":"Stacchiotti","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"2023061410240644900_DMM049649C46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejca.2018.10.024","article-title":"Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study","volume":"106","author":"Stacchiotti","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"2023061410240644900_DMM049649C47","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/cancers11071015","article-title":"Comparative assessment of antitumor effects and autophagy induction as a resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft","volume":"11","author":"Stacchiotti","year":"2019","journal-title":"Cancers"},{"key":"2023061410240644900_DMM049649C48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12885-017-3091-1","article-title":"Mechanism of action of trabectedin in desmoplastic small round cell tumor cells","volume":"17","author":"Uboldi","year":"2017","journal-title":"BMC Cancer"},{"key":"2023061410240644900_DMM049649C49","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1038\/s41418-021-00823-x","article-title":"Ki-67 gene expression","volume":"28","author":"Uxa","year":"2021","journal-title":"Cell Death Differ."},{"key":"2023061410240644900_DMM049649C50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/CAD.0000000000000435","article-title":"Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series","volume":"28","author":"Verret","year":"2017","journal-title":"Anti-Cancer Drugs"},{"key":"2023061410240644900_DMM049649C51","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.18632\/oncotarget.3538","article-title":"PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins","volume":"6","author":"Zuco","year":"2015","journal-title":"Oncotarget"}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.049649\/2824449\/dmm049649.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.049649\/2954608\/dmm049649.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.049649\/2954608\/dmm049649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T06:24:32Z","timestamp":1686723872000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/16\/6\/dmm049649\/316733\/Effectiveness-of-irinotecan-plus-trabectedin-on-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.049649","relation":{},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"dmm049649"}}